“This is a very exciting opportunity for the development and commercialization of our stem cell product EQSTEM for the treatment of joint disease in horses. Xintela will actively participate in the development of EQSTEM, among other things, through process development and production of EQSTEM, on a fully funded, non-dilutive basis. Through this collaboration with EQGen Biomedical, we also get an excellent team associated with Regen Biomedical and Hummingbird Biomedical, with extensive experience in regenerative medicine, production, clinical development, business development as well as capital raising. We are very much looking forward to completing this license agreement and getting started on the collaboration with EQGen Biomedical”, says Xintela's CEO Evy Lundgren-Åkerlund.

“I believe Xintela’s unique equine stem cell product EQSTEM, purified using the stem cell marker integrin α10β1, has real potential to treat equine inflammatory and degenerative joint diseases, with current unmet medical need in approximately 30% of equines. EQGen Biomedical, is poised for success and with our deep expertise in clinical development as well as infrastructure for the development of regenerative therapies, we will be able to progress the clinical development of EQSTEM. I am very much looking forward to our collaboration”, says EQGen Biomedical’s Chief Medical Officer, Willem Scheele.